[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.41.181. Please contact the publisher to request reinstatement.
Sign In
Individual Sign In
Create an Account
Institutional Sign In
OpenAthens Shibboleth
[Skip to Content Landing]
Article
August 1974

Inhibition of Leukocyte Migration by Human TumorsEffect on Patient Survival

Author Affiliations

From the Department of Surgery, Division of Clinical Oncology, University of Wisconsin, Center for Health Sciences, Madison, Wis.

Arch Surg. 1974;109(2):211-214. doi:10.1001/archsurg.1974.01360020073014
Abstract

Survival was determined in 41 patients whose tumors contained varying amounts of substances that inhibited leukocyte migration in vitro. Twenty-two of 28 patients whose tumors inhibited leukocyte migration less than 25% lived at least 24 months following diagnosis. Only three of 13 patients whose tumors inhibited leukocyte migration 25% or more survived for a similar period. Since tumor preparations inhibit migration of both autogenous and allogeneic leukocytes, the possibility of nonimmunologic mediation was considered. Leukocyte migration was inhibited by substances known to increase adenosine 3':5'-cyclic monophosphate. Production of such substances could be the mechanism by which tumor preparations inhibit leukocyte migration.

References
1.
Hellström IE, et al:  Demonstration of cell-bound and humoral immunity against neuroblastoma cells . Proc Natl Acad Sci USA 62:1231-1238, 1968.Article
2.
Hellström I, et al:  Cellular and humoral immunity to different types of human neoplasms . Nature 220:1352-1354, 1968.Article
3.
Baldwin RW, Embleton MJ, Robins RA:  Cellular and humoral immunity to rat hepatoma-specific antigens correlated with tumor status . Int J Cancer 11:1-10, 1973.Article
4.
Hellström I, et al:  Serum-mediated protection of neoplastic cells from inhibition by lymphocytes immune to their tumor-specific antigens . Proc Natl Acad Sci USA 62:362-368, 1969.Article
5.
Sjögren HO, et al:  Suggestive evidence that the "blocking antibodies" of tumor-bearing individuals may be antigen-antibody complexes . Proc Natl Acad Sci USA 68:1372-1375, 1971.Article
6.
Baldwin RW, Price MR, Robins RA:  Blocking of lymphocytemediated cytotoxicity for rat hepatoma cells by tumor-specific antigen-antibody complexes . Nature 238:185-187, 1972.Article
7.
Bansal SC, Sjögren HO:  Counteraction of the blocking of cellmediated tumor immunity by inoculation of unblocking sera and splenectomy: Immunotherapeutic effects on primary polyoma tumors in rats . Int J Cancer 9:490-509, 1972.Article
8.
Rebuck JW, Crowley JH:  A method of studying leukocyte functions in vivo . Ann NY Acad Sci 59:757-805, 1955.Article
9.
Dizon QS, Southam CM:  Abnormal cellular response to skin abrasion in cancer patients . Cancer 16:1288-1292, 1963.Article
10.
Goldsmith HS, Levin AG, Southam CM:  A study of cellular responses in cancer patients by qualitative and quantitative Rebuck tests . Surg Forum 16:102-104, 1965.
11.
Eilber FR, Morton DL:  Impaired immunologic reactivity and recurrence following cancer surgery . Cancer 25:362-367, 1970.Article
12.
Johnson MW, Maibach HI, Salmon S:  Skin reactivity in patients with cancer: Impaired delayed hypersensitivity or faculty inflammatory response? N Engl J Med 284:1255-1257, 1971.Article
13.
Bach ML, et al:  Lymphocyte reactivity in vitro: VII. The effect of polymorphonuclear leukocytes on lymphocyte response . Transplantation 12:283-286, 1971.Article
14.
Andersen V, et al:  Effect of autologous mammary tumor extracts on human leukocyte migration in vitro . Int J Cancer 5:357-363, 1970.Article
15.
Bloom BR, et al:  Demonstration of delayed hypersensitivity to soluble antigens of chemically induced tumors by inhibition of macrophage migration . Proc Natl Acad Sci USA 64:1176-1180, 1969.Article
16.
Cochran AJ, et al:  Postoperative depression of tumor-directed cell-mediated immunity in patients with malignant disease . Br Med J 4:67-70, 1972.Article
17.
Wolberg WH:  Inhibition of migration of human autogenous and allogeneic leukocytes by extracts of patient's cancer . Cancer Res 31:798-802, 1971.
18.
Chretien PB, et al:  Correlation of preoperative lymphocyte reactivity with the clinical course of cancer patients . Surg Gynecol Obstet 136:380-384, 1973.
19.
Sample WF, Gertner HR, Chretien PB:  Inhibition of phytohemagglutinin-induced in vitro lymphocyte transformation by serum from patients with carcinoma . J Natl Cancer Inst 46:1291-1297, 1971.
20.
Silk M:  Effect of plasma from patients with carcinoma on in vitro lymphocyte transformation . Cancer 20:2088-2089, 1967.Article
21.
Whittaker MG, Clark CG:  Depressed lymphocyte function in carcinoma of the breast . Br J Surg 58:717-720, 1971.Article
22.
Lowry OH, et al:  Protein measurement with the Folin phenol reagent . J Biol Chem 193:265-275, 1951.
23.
Bloom BR, Bennett B:  Mechanism of a reaction in vitro associated with delayed-type hypersensitivity . Science 153:80-82, 1966.Article
24.
George M, Vaughan JH:  In vitro cell migration as a model for delayed hypersensitivity . Proc Soc Exp Biol Med 111:514-521, 1962.Article
25.
Rochlin RE, Meyers OL, David JR:  An in vitro assay for cellular hypersensitivity in man . J Immunol 104:95-102, 1970.
26.
Senyk G, Hadley WK:  In vitro correlates of delayed hypersensitivity in man: Ambiguity of polymorphonuclear neutrophils as indicator cells in leukocyte migration test : Infect Immunity 8:370-380, 1973.
27.
Johnson GS, Morgan WD, Pastan I:  Regulation of cell motility by cyclic AMP . Nature 235:54-56, 1972.Article
28.
Pick E:  Cyclic AMP affects macrophage migration . Nature 238:176-177, 1972.
29.
Estensen RD, et al:  Cyclic GMP and cell movement . Nature 245:458-460, 1973.Article
30.
Koopmen WJ, Gillis MH, David JR:  Prevention of MIF activity by agents known to increase cellular cyclic AMP . J Immunol 110:1609-1614, 1973.
×